EUCTR2004-004327-35-DE进行中(未招募)不适用
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Be aged >or= 55 years, 7 years of education at least, LM II of WMS-Revised with 1.5 SD below norm as function of age, MMSE >or= 24, global CDR=0.5 (memory box >or= 0.5), not sufficiently impaired to meet dementia (DSM IV).AchEI are to be stopped at least 3 months before selection. SSRI or SNRI for depressive symptoms accepted if stabilized symptoms for at least 3 consecutive months before selection; the same for low dose of anxiolytic or hypnotic, used as sleep aid.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient sufficiently impaired to meet DSM-IV criteria for diagnosis of dementia
- •- Vascular disorder (modified Hachinski Ischemic Scale score > 4),
- •- History of Major Depressive Episode or other major psychiatric disorder within
- •12 months prior to randomization (DSM-IV),
- •- Depression symptoms assessed with the Geriatric Depression Scale, GDS-15> 6 ,
- •- Hamilton Rating Scale for Anxiety, HAM-A scale >15 ,
- •- Any other previous or ongoing chronic or recurrent disease of the central nervous system or psychiatric diseases, that may have an impact on cognitive performance, left to the AD research clinician’s judgement,
- •- Concomitant treatments known to have central effects except for restricted treatments such as :
- •. SSRI or SNRI administered for stabilized depressive symptoms for at least 3 months (same treatment and same daily dose for at least 3 consecutive months before selection with treatment to be continued at the same dose for the study duration) and
- •. Low dose of anxiolytic or hypnotic used as sleep aid (benzodiazepine or other, e.g. 2 mg of lorazepam, 0.25 mg of alprazolam, 15 mg of oxazepam or 10 mg of temazepam, same treatment and same nocte dose for at least 3 consecutive months before selection).
研究者
相似试验
进行中(未招募)
1 期
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.EUCTR2004-004327-35-GBInstitut de Recherches Internationales Servier450
进行中(未招募)
不适用
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period.An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.Mild Cognitive ImpairmentMedDRA version: 5.1Level: PTClassification code 10027175EUCTR2004-004327-35-BEInstitut de Recherches Internationales Servier450
终止
2 期
Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment PatientsMild Cognitive ImpairmentNCT00202540Institut de Recherches Internationales Servier38
招募中
不适用
Evaluation of effects on cognitive function and swallowing activity following after continuous chewing training with chewing start food of process lead in cerebrovascular disease: an open-label, randomized controlled.Cerebral vascular diseaseJPRN-UMIN000029603Medical corporation Sonodakai Takenotsuka Noushinkei Rehabilitation Hospital20
已完成
不适用
Effect of WS-5 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, multi-center, Randomized, Double-blind, Placebo-Controlled Clinical TrialKCT0003695Chung-Ang Univerisity Hospital90
